Severe Alopecia Areata Therapeutics
1. Leqselvi patent expiration
Treatment: Treatment of adult patients with alopecia areata
LEQSELVI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12247034 | SUN PHARM INDS INC | Crystalline form of deuruxolitinib phosphate |
May, 2044
(18 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12285432 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
Aug, 2042
(16 years from now) | |
| US12364699 | SUN PHARM INDS INC | NA |
Oct, 2044
(18 years from now) | |
| US11919907 | SUN PHARM INDS INC | Deuterated JAK inhibitor and uses thereof |
May, 2041
(15 years from now) | |
| US10561659 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(11 years from now) | |
| US12076323 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 25, 2029 |
Drugs and Companies using DEURUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 25 July, 2028
Market Authorisation Date: 25 July, 2024
Dosage: TABLET
More Information on Dosage
LEQSELVI family patents
2. Litfulo patent expiration
Treatment: Method of treating severe alopecia areata in adults and adolescents 12 years and older by administering ritlectinib
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12116368 | PFIZER | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto |
Oct, 2041
(15 years from now) | |
| US9617258 | PFIZER | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Dec, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12077533 | PFIZER | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Dec, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2028 |
Drugs and Companies using RITLECITINIB TOSYLATE ingredient
NCE-1 date: 24 June, 2027
Market Authorisation Date: 23 June, 2023
Dosage: CAPSULE
More Information on Dosage
LITFULO family patents